Please login to the form below

Not currently logged in
Email:
Password:

Eisai establishes neuroscience unit in Belgium and Luxembourg

Follows the company's recent expansion in Australia

EISAI 

Eisai has expanded its European operations, adding a neuroscience business unit to its Belgian and Luxembourg business.

The new unit will market the company's epilepsy drug Fycompa (perampanel), which it has been giving a rolling launch across the region.

Dr Nicolas Kormoss, medical director for Belgium and Luxembourg at Eisai EMEA, said: “We are excited to announce the launch of our neuroscience capability in Belgium, which will provide greater access to our innovative portfolio of epilepsy treatments, including newly launched perampanel.”

The neuroscience unit will also be responsible for Inovelon (rufinamide), an adjunctive therapy for the treatment of epileptic seizures associated with Lennox-Gastaut syndrome (LGS) in patients 4 years and older.

Fycompa indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.

Eisai first introduced Fycompa in Europe in 2012 when it launched the drug in the UK - it has since been introduced in markets such as France, Switzerland, the Netherlands and, more problematically for Eisai, Germany.

Last week, the country's Federal Joint Committee (G-BA) concluded that Fycompa offers no additional benefit over existing drugs on the market for the treatment of epilepsy and could only be reimbursed if it was priced at the same level as generics.

Eisai's decision to expand its Belgium and Luxembourg operations comes after its recent Australian expansion, which saw the opening of an office in Melbourne.

Article by
Kirstie Pickering

14th November 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics